睿智医药涨2.40%，成交额1.04亿元，主力资金净流入182.84万元

Core Viewpoint - The stock of Ruizhi Pharmaceutical has shown significant growth this year, with a notable increase in both revenue and net profit, indicating strong performance in the pharmaceutical outsourcing sector [1][2]. Group 1: Stock Performance - On November 14, Ruizhi Pharmaceutical's stock rose by 2.40%, reaching a price of 11.52 yuan per share, with a trading volume of 1.04 billion yuan and a turnover rate of 1.94%, resulting in a total market capitalization of 57.37 billion yuan [1]. - Year-to-date, the stock price has increased by 79.44%, with a 6.47% rise over the last five trading days, a 2.58% increase over the last 20 days, and a 10.70% decline over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent instance on July 29, where it recorded a net buy of 1.65 billion yuan [1]. Group 2: Financial Performance - For the period from January to September 2025, Ruizhi Pharmaceutical achieved a revenue of 8.17 billion yuan, reflecting a year-on-year growth of 13.68%, while the net profit attributable to shareholders was 709.13 million yuan, marking a substantial increase of 111.50% [2]. - The company has distributed a total of 1.80 billion yuan in dividends since its A-share listing, with no dividends paid in the last three years [2]. Group 3: Shareholder Information - As of October 31, 2025, the number of shareholders for Ruizhi Pharmaceutical was 42,100, a decrease of 0.88% from the previous period, with an average of 11,260 circulating shares per shareholder, which is an increase of 0.89% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 24.33 million shares, having decreased its holdings by 6,100 shares compared to the previous period [2].